IP Library Granted Patent US 11,478,498
Granted Patent B2
US 11,478,498 · App. 16/853,361 · Granted Oct 25, 2022

Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent

Inventors: Yunik Chang (Clermont, FL); Gordon J. Dow (Greenbrae, CA); Radhakrishnan Pillai (Santa Rosa, CA)
Assignee: Dow Pharmaceutical Sciences, Inc.
A61K31/7056A61K8/0241A61K8/042A61K8/044A61K8/345A61K8/38A61K8/55A61K9/0014A61K9/14A61K31/075A61K31/235A61K31/327A61K45/06A61K47/10A61K47/32A61Q19/00A61K2800/33A61K2800/413
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,478,498
App. No.
16/853,361
Granted
Oct 25, 2022
Kind
B2
Abstract

An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.

Claims (12)

1. A method for treating acne rosacea, comprising applying to the skin of a patient in need thereof an aqueous suspension formulation comprising 2.5% w/w to 4.5% w/w benzoyl peroxide, about 1.2% w/w clindamycin phosphate, propylene glycol, a gelling agent, and water;

wherein the combined concentration of water and propylene glycol is sufficient to provide a suspension of benzoyl peroxide in a saturated solution of benzoyl peroxide,

wherein the ratio of water to propylene glycol in the formulation ranges from 12:1 to 20:1,

wherein the concentration of the propylene glycol is one to four times the concentration of the benzoyl peroxide, and

wherein the formulation is applied once a day for up to 12 weeks to the skin of the patient.

2. The method of claim 1 , wherein the concentration of benzoyl peroxide in the formulation ranges from 2.5% to 3.5% w/w.

3. The method of claim 1 , wherein the concentration of benzoyl peroxide in the formulation is about 3.5% w/w.

4. The method of claim 1 , wherein the concentration of propylene glycol in the formulation is about 5.0% w/w and the ratio of water to propylene glycol in the formulation ranges from 12:1 to 18:1.

5. The method of claim 1 , wherein the gelling agent is selected from the group consisting of hydroxypropylcellulose, hydroxyethylcellulose, a carboxyvinyl polymer, polyvinyl alcohol, a polyethylene oxide, a propylene glycol alginate, methylcellulose, hydroxypropylmethylcellulose, xanthan gum, and carrageenan.

6. The method of claim 5 , wherein the gelling agent is a carboxyvinyl polymer.

7. The method of claim 1 , wherein the formulation is free of surfactant.

8. The method of claim 1 , wherein the formulation contains a surfactant.

Assignments (10)
U.S. PATENT SECURITY AGREEMENT Recorded Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2022
From: DOW PHARMACEUTICAL SCIENCES, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 061702/0675 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2020
From: CHANG, YUNIK; DOW, GORDON J.; PILLAI, RADHAKRISHNAN
To: DOW PHARMACEUTICAL SCIENCES, INC.
Reel/Frame 052524/0836 →